Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - baclofen, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - sintetica baclofen intrathecal is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - baclofen, quantity: 50 microgram/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - sintetica baclofen intrathecal is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - orlistat, quantity: 120 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; sodium starch glycollate type a; hydrophobic colloidal silica anhydrous; microcrystalline cellulose; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin - prolistat is indicated for the treatment of obese patients with a body mass index (bmi) ? 30, and overweight patients with a bmi ? 27 in the presence of other risk factors, in conjunction with a mildly hypocaloric diet.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - clindamycin hydrochloride, quantity: 162.87 mg (equivalent: clindamycin, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; purified talc; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate; carmoisine; patent blue v - clindamycin bnm (clindamycin hydrochloride) capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin bnm capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. ,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. ,anaerobes serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. ,streptococci serious respiratory tract infections; serious skin and skin structure infections, septicaemia. ,staphylococci serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis. ,pneumococci serious respiratory tract infections. ,adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy. ,bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ropivacaine hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride; sodium hydroxide - surgical anaesthesia (adults and children over 12 years of age),? epidural block for surgery including caesarean section,? intrathecal anaesthesia,? field block (minor nerve block and infiltration),? major nerve block,analgesia (adults and children over 12 years of age),? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,? field block (minor nerve block and infiltration),? continuous peripheral nerve block infusion or intermittent injections for post operative pain management,? continuous wound infusion for postoperative pain management (adults only),analgesia (children aged 0 - 12 years),? caudal epidural block in neonates (> 37 weeks gestation and over 2,500 g weight), infants and children up to and including 12 years,? continuous epidural infusion in infants (> 30 days and over 2,500 g weight) and children up to and including 12 years,? peripheral nerve block in children aged 1 up to and including 12 years,for peri- and postoperative pain management.,there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ropivacaine hydrochloride, quantity: 7.5 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; hydrochloric acid - surgical anaesthesia (adults and children over 12 years of age),? epidural block for surgery including caesarean section,? intrathecal anaesthesia,? field block (minor nerve block and infiltration),? major nerve block,analgesia (adults and children over 12 years of age),? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,? field block (minor nerve block and infiltration),? continuous peripheral nerve block infusion or intermittent injections for post operative pain management,? continuous wound infusion for postoperative pain management (adults only),analgesia (children aged 0 - 12 years),? caudal epidural block in neonates (> 37 weeks gestation and over 2,500 g weight), infants and children up to and including 12 years,? continuous epidural infusion in infants (> 30 days and over 2,500 g weight) and children up to and including 12 years,? peripheral nerve block in children aged 1 up to and including 12 years,for peri- and postoperative pain management.,there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ropivacaine hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid; sodium chloride - surgical anaesthesia (adults and children over 12 years of age),? epidural block for surgery including caesarean section,? intrathecal anaesthesia,? field block (minor nerve block and infiltration),? major nerve block,analgesia (adults and children over 12 years of age),? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,? field block (minor nerve block and infiltration),? continuous peripheral nerve block infusion or intermittent injections for post operative pain management,? continuous wound infusion for postoperative pain management (adults only),analgesia (children aged 0 - 12 years),? caudal epidural block in neonates (> 37 weeks gestation and over 2,500 g weight), infants and children up to and including 12 years,? continuous epidural infusion in infants (> 30 days and over 2,500 g weight) and children up to and including 12 years,? peripheral nerve block in children aged 1 up to and including 12 years,for peri- and postoperative pain management.,there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ropivacaine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; sodium chloride; water for injections - surgical anaesthesia (adults and children over 12 years of age),? epidural block for surgery including caesarean section,? intrathecal anaesthesia,? field block (minor nerve block and infiltration),? major nerve block,analgesia (adults and children over 12 years of age),? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,? field block (minor nerve block and infiltration),? continuous peripheral nerve block infusion or intermittent injections for post operative pain management,? continuous wound infusion for postoperative pain management (adults only),analgesia (children aged 0 - 12 years),? caudal epidural block in neonates (> 37 weeks gestation and over 2,500 g weight), infants and children up to and including 12 years,? continuous epidural infusion in infants (> 30 days and over 2,500 g weight) and children up to and including 12 years,? peripheral nerve block in children aged 1 up to and including 12 years,for peri- and postoperative pain management.,there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ropivacaine hydrochloride, quantity: 7.5 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; sodium chloride; water for injections - surgical anaesthesia (adults and children over 12 years of age),? epidural block for surgery including caesarean section,? intrathecal anaesthesia,? field block (minor nerve block and infiltration),? major nerve block,analgesia (adults and children over 12 years of age),? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,? field block (minor nerve block and infiltration),? continuous peripheral nerve block infusion or intermittent injections for post operative pain management,? continuous wound infusion for postoperative pain management (adults only),analgesia (children aged 0 - 12 years),? caudal epidural block in neonates (> 37 weeks gestation and over 2,500 g weight), infants and children up to and including 12 years,? continuous epidural infusion in infants (> 30 days and over 2,500 g weight) and children up to and including 12 years,? peripheral nerve block in children aged 1 up to and including 12 years,for peri- and postoperative pain management.,there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ropivacaine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - surgical anaesthesia (adults and children over 12 years of age),? epidural block for surgery including caesarean section,? intrathecal anaesthesia,? field block (minor nerve block and infiltration),? major nerve block,analgesia (adults and children over 12 years of age),? continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain,? field block (minor nerve block and infiltration),? continuous peripheral nerve block infusion or intermittent injections for post operative pain management,? continuous wound infusion for postoperative pain management (adults only),analgesia (children aged 0 - 12 years),? caudal epidural block in neonates (> 37 weeks gestation and over 2,500 g weight), infants and children up to and including 12 years,? continuous epidural infusion in infants (> 30 days and over 2,500 g weight) and children up to and including 12 years,? peripheral nerve block in children aged 1 up to and including 12 years,for peri- and postoperative pain management.,there are no safety or efficacy data to support the use of ropivacaine for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).